Dr. Donald Bruce Kirchner, Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 5299 Spring Grove Ave, Cincinnati, OH 45217 Phone: 513-627-4385 Fax: 513-530-6657 |
Mr. Hal Samuel Blatman, M.D. Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine Medicare: Not Enrolled in Medicare Practice Location: 10653 Techwood Cir, Suite 101, Cincinnati, OH 45242 Phone: 513-956-3200 Fax: 513-956-3202 |
Dr. Peter H Lowry, MD Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine Medicare: Not Enrolled in Medicare Practice Location: 5600 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-965-9960 Fax: 513-965-9666 |
Dr. Cherryl June Christensen, D.O. Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 2 Procter And Gamble Plz, Tn-4 #485, Cincinnati, OH 45202 Phone: 513-983-1006 Fax: 513-277-2059 |
Dr. Herman K. Hobohm, M.D. Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine Medicare: Not Enrolled in Medicare Practice Location: 3801 Hauck Rd, Cincinnati, OH 45241 Phone: 513-563-1505 Fax: 513-769-4776 |
Dr. Victoria Wells Wulsin, MD, DRPH Preventive Medicine - Public Health & General Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2751 Ovarsity Way, Cincinnati, OH 45221 Phone: 513-556-2564 Fax: 513-556-1337 |
News Archive
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Many people spend increasing time sitting during their work days, but breaking things up with regular brisk walks, while also taking daily 30-minute walks, significantly lowers levels of fatty acids that lead to clogged arteries, researchers from New Zealand's University of Otago have found in a first-of-its-kind study.
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance. This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.
Eisai Inc. announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for partial-onset seizures associated with epilepsy to the U.S. Food and Drug Administration (FDA) on December 22, 2011.
An inexpensive, FDA-approved drug - cholestyramine - taken in conjunction with an antibiotic prevents the antibiotic from driving antimicrobial resistance, according to new research by scientists at Penn State and the University of Michigan. The team's findings appear today (Dec. 1) in the journal eLife.
› Verified 5 days ago